Skip to main content
Fig. 3 | Diabetology & Metabolic Syndrome

Fig. 3

From: Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus

Fig. 3

Luseogliflozin suppresses HFDT-induced activation of hepatic stellate cells and inflammation in the liver. a Immunostaining with anti-SMA antibody, as a marker of stellate cell activation. Representative photographs of each group are shown. b mRNA levels of SMA and TIMP1. c The mRNA levels of MCP-1, IL-1β, IL-6 IL-12 and F4/80. All data are shown as means + SEM

Back to article page